0B68 Cristofanilli, Massimo - Thomas Jefferson University - Thomas Jefferson University

Massimo Cristofanilli, MD

Contact Dr. Cristofanilli

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Molecular characterization and targeted therapeutic approaches in breast cancer
  2. Circulating tumor cells in newly diagnosed inflammatory breast cancer
  3. Neoadjuvant model in cancer treatment: From clinical opportunity to health-care utility
  4. Cytometric characterization of Circulating Tumor Cells Captured by microfiltration and their correlation to the cellsearch® CTC test
  5. Inflammatory breast cancer management in the National Comprehensive Cancer Network: The disease, recurrence pattern, and outcome
  6. IBC as a rapidly spreading systemic disease: Clinical and targeted approaches using the neoadjuvant model
  7. Outcomes after multidisciplinary treatment of inflammatory breast cancer in the era of neoadjuvant HER2-directed therapy
  8. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer
  9. Relationship between circulating tumor cells, blood coagulation, and urokinase-plasminogen-activator system in early breast cancer patients
  10. International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013)
  11. Palbociclib in hormone-receptor-positive advanced breast cancer
  12. Using circulating tumor cells to guide therapy in breast cancer: Could this replace biopsies?
  13. Cancer stem cells: implications for cancer therapy
  14. CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines
  15. TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients
  16. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limite 07BF d metastatic dissemination
  17. Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy
  18. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: Preclinical activity in HER2 non-amplified inflammatory breast cancer models
  19. Emergence of constitutively active estrogen receptor-╬▒ mutations in pretreated advanced estrogen receptor-positive breast cancer
  20. Circulating giant macrophages as a potential biomarker of solid tumors